Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

In a report released on January 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Climb Bio (CLYM – Research Report). The company’s shares closed last Friday at $2.00.

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Leerink Partnrs issued their FY2029 ... additional 93 shares during the last quarter. Quest Partners LLC purchased a new stake in Vaxcyte during ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partners ...

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price hoisted by equities researchers at Leerink Partners from $490.00 to $548.00 in a report issued on Monday. Leerink Partners ...